The share of Pfizer’s cytarabine is dominating the Chinese market or even in the global market. The cytarabine referred to here is Pfizer’s product Cytosar™ which is the trade name, and its generic name is Cytarabine for Injection. It is mainly indicated for remission induction and maintenance therapy in acute non-lymphocytic leukemia of adults and children and also has therapeutic effects in other types of leukemia. According to a notice on the internet at the beginning of this year, Pfizer would conduct equipment overhaul for the production line of cytarabine, and cytarabine would be suspended production for a period of time due to the long overhaul and maintenance time. As a result, the shortage of cytarabine has been widely reported recently in China.
